Physician profile
Dalya Shamon
NPI 1164657805
$8,511.54
in general payments reported to CMS, 2019-2025
50 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $615 · 2021: $991 · 2022: $1,170 · 2023: $1,665 · 2024: $1,861 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,444.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $849.71 | 2020-2025 | Nayzilam, Briviact, Fintepla |
| Novo Nordisk INC | $650.58 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $635.19 | 2021-2025 | Qulipta, Ubrelvy, Linzess |
| Amgen INC. | $630.81 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $494.63 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $488.50 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $434.19 | 2019-2024 | Mounjaro, Emgality, Amyvid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.11 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.17 | 2021-2025 | Jardiance, Tradjenta |
| Sumitomo Pharma America, INC. | $274.19 | 2023-2025 | Gemtesa |
| Neurelis, INC. | $260.51 | 2023-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $246.04 | 2020-2025 | Airsupra |
| Avanir Pharmaceuticals, INC. | $228.15 | 2019-2022 | |
| Lundbeck LLC | $219.87 | 2024-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $205.98 | 2023-2024 | Rexulti, Nuedexta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalya Shamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.